The regulatory status applies to AP-SA02, an intravenous treatment designed to manage complicated bacteremia caused by both methicillin-sensitive and methicillin-resistant Staphylococcus aureus. By securing this designation, Armata gains access to an expedited review process intended for therapies that demonstrate substantial clinical improvement over existing options for life-threatening conditions.
In section Market Quotes
Armata Pharmaceuticals Stock Climbs on FDA Designation
A 10% jump in Armata Pharmaceuticals shares greeted the market Monday morning following news that the Food and Drug Administration granted breakthrough therapy designation to the company’s lead antibacterial candidate. The stock reached $5.92 in premarket trading, offering a brief reprieve after a 14% decline since the start of the year.
Management intends to coordinate closely with federal regulators to accelerate the development timeline for the candidate. Complicated S. aureus bloodstream infections currently represent a significant medical challenge, characterized by high rates of relapse and mortality. This development marks a pivot for the firm as it attempts to move the product candidate toward potential patient use.
Comments (0)
No comments yet. Be the first!